BRIACELL THERAPEUTICS -CW27 (BCTXW)
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are experiencing notable movement on Thursday?
Which stocks are moving on Thursday?
Let's have a look at the top gainers and losers in the middle of the day of today's session.
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
BriaCell’s clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in...
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
Five BriaCell poster presentations to highlight updated survival and key biomarker data from Phase 2 trial of Bria-IMT™ plus immune check point inhibitor...
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
55% of BriaCell patients1 remained alive one year since enrollment in BriaCell’s Phase 2 study, markedly exceeding the survival rate of current standard of...
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)Primary...
BriaCell Therapeutics Announces Closing of $5 Million Offering
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Therapeutics Announces $5 Million Offering
Priced At-the-Market Under Nasdaq Rules...
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor
Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with “Eye-Bulging” metastatic breast...
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will...
BriaCell Therapeutics Announces Closing of $8.5 Million Offering
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Therapeutics Announces $8.5 Million Offering
Priced At-the-Market Under Nasdaq Rules...
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months...
BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer
BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancerThe...
BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3Significant...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS...
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression...
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson...
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve...
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS...
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),...
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control...
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of activating multiple types of immune cells,...
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell”...
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer
Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cyclesPowerful anti-tumor response associated with reduction in...
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients
71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™,...
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset
In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell’s combination regimen exceeded that of similar...
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the...
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
BriaCell’s Bria-IMT™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning “Cold” tumors “Hot” on ImmunoPET...
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the...
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND
BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies...
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology
According to American Cancer Society Facts and Figures, breast cancer is the most common cancer in the United States with 300,590 expected new cases in...
BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic
Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for...